New Clinical Trials, Stock Price Movements, and Completed Acquisitions - Research Report on Merck, Lilly, Allergan, PerkinElmer, and Air Methods
NEW YORK, December 23, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Merck & Co., Inc. (NYSE: MRK), Eli Lilly & Co. (NYSE: LLY), Allergan Inc. (NYSE: AGN), PerkinElmer Inc. (NYSE: PKI), and Air Methods Corp. (NASDAQ: AIRM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Merck & Co., Inc. Research Report
On December 18, 2013, Merck & Co., Inc. (Merck) announced the initiation of a clinical trial to evaluate the combination of the Company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. According to Merck, it has entered into collaboration with GlaxoSmithKline to study MK-3475 with pazopanib and other agents in the GlaxoSmithKline portfolio in the future. Merck said that this Phase I/II clinical trial is designed to evaluate the safety and efficacy of a combination of MK-3475 and pazopanib in treatment naïve patients with advanced renal cell carcinoma. Commenting on the news, Iain Dukes, Senior Vice President, Licensing and External Scientific Affairs, Merck Research Laboratories, said, "Collaborations like this are central to Merck's strategy to evaluate the potential of MK-3475 for the treatment of cancer. We look forward to initiating further collaborations to investigate MK-3475 in combination with other anti-cancer agents across a range of tumor types." However, the Companies did not disclose further details about the collaboration. The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Eli Lilly & Co. Research Report
On December 18, 2013, Eli Lilly & Co.'s (Lilly) stock rose 2.62%, ending the day at $50.51. Over the previous three trading sessions, shares of Lilly gained 2.27%, compared to the Nasdaq Composite which gained 1.73% during the same period. The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Allergan Inc. Research Report
On December 18, 2013, Allergan Inc.'s (Allergan) stock rose 2.08%, ending the day at $101.13. Over the previous three trading sessions, shares of Allergan gained 4.72%, compared to the S&P 500 which gained 1.99% during the same period. The Full Research Report on Allergan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
PerkinElmer Inc. Research Report
On December 16, 2013, PerkinElmer Inc. (PerkinElmer) announced that the Company will present its industry-leading products and services at the Isranalytica 2014 conference in Tel Aviv, Israel, on January 8, 2014 to January 9, 2014, at the David Intercontinental Hotel in the PerkinElmer Lounge. The Company reported that visiting PerkinElmer at Isranalytica 2014 will help interested parties learn more about the New AxIONiQT GC/MS/MS, the DairyGuard Milk Powder Analyzer, the NexION 300 ICP-MS, the GC SNFR Olfactory Port, the TMA 4000, the LabChip GXII, and Alpha Technology. Aaron Geist, PerkinElmer Israel General Manager, said, "PerkinElmer technologies have been exhibited at Isranalytica in the past, but we are extremely pleased to directly participate for the first time since establishing our new operations in August 2013. We are committed to investing in Israel, building strategic relationships, and offering customers our knowledge, expertise and advanced capabilities to help them solve the most pressing issues in human and environmental health."The Full Research Report on PerkinElmer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Air Methods Corp. Research Report
On December 16, 2013, Air Methods Corp. (Air Methods) announced that the Company has successfully completed its acquisition of Blue Hawaiian Helicopters and its affiliates (Blue Hawaiian). According to Air Methods, Blue Hawaiian operates a fleet of 24 helicopters consisting of Eurocopter AS350s and EC130s. Commenting on the acquisition, Aaron Todd, Air Methods' CEO, said, "Air Methods is very pleased to have completed the acquisition of Blue Hawaiian, a 'blue chip' tour company with best-in-class air fleet, pilots, management and tours. The addition of Blue Hawaiian significantly strengthens Air Methods' Tourism Division and continues our focus on vertical integration and the search for key aviation adjacencies to our core business. We look forward to Blue Hawaiian joining the Air Methods family." The Full Research Report on Air Methods Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner